Explore Your Topic

Latest News

Share Price/Index

Local News

September 01, 2020

Bayer launches Proline® GOLD for premium protection against sclerotinia in canola

Read more
August 14, 2020

Bayer to acquire UK-based biotech KaNDy Therapeutics Ltd.

• Further expansion of Bayer’s drug development pipeline in Women’s Healthcare • Innovative non-hormonal oral compound NT-814 being studied to alleviate menopausal symptoms • Development compound recently completed Phase IIb • Reinforces Bayer’s position in Women’s Healthcare Read more
August 04, 2020

Bayer’s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes

• Finerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care • Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events • Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized • Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes Read more
Bayer News Overview

Global News

September 09, 2020

Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases

Read more

Advance Your Career

Jobs at Bayer Canada

  • Interested in working for us? See if there are job openings in Canada.

  • read more

Our Businesses

We research, develop and market innovative products that improve the health of people and plants. Our business comprises three core divisions and one business unit. Learn more about it here.

Last updated: August 21, 2020